Gyawali Bishal
Institute of Cancer Policy, King's College London, Guy's Hospital Campus, Great Maze Pond Road, London SE1 9RT, UK.
Ecancermedicalscience. 2017 Dec 6;11:ed75. doi: 10.3332/ecancer.2017.ed75. eCollection 2017.
OlympiAD was a phase 3 randomized controlled trial of a PARP inhibitor olaparib for metastatic HER2 negative breast cancer patients harboring a BRCA mutation. Although the OlympiAD trial met its primary endpoint, there are concerns regarding whether olaparib truly improves meaningful outcomes for these patients. In this editorial, I examine these issues in detail. An exploration of these issues will provide important educational insights for oncologists and cancer policy makers. I conclude that although olaparib seems to have won the Gold with OlympiAD, the patients probably have not. We need to stop celebrating a gold-plated bronze as a true gold so that one day our patients can finally get the gold they deserve.
OlympiAD是一项针对携带BRCA突变的转移性HER2阴性乳腺癌患者的PARP抑制剂奥拉帕利的3期随机对照试验。尽管OlympiAD试验达到了其主要终点，但对于奥拉帕利是否真的能改善这些患者的有意义结局仍存在担忧。在这篇社论中，我将详细探讨这些问题。对这些问题的探讨将为肿瘤学家和癌症政策制定者提供重要的教育启示。我的结论是，尽管奥拉帕利似乎凭借OlympiAD试验获得了金牌，但患者可能并未受益。我们需要停止将镀金的铜牌当作真正的金牌来庆祝，以便有朝一日我们的患者最终能够获得他们应得的金牌。
